Macrophages in immunopathology of atherosclerosis: A target for diagnostics and therapy

Current Pharmaceutical Design

Volumn 21, Issue 9, 2015, Pages 1172-1179

  Orekhov, Alexander N ^a,b   Sobenin, Igor A ^b,c   Gavrilin, Mikhail A ^d   Gratchev, Alexei ^a,e   Kotyashova, Svetlana Y ^a   Nikiforov, Nikita G ^b,c   Kzhyshkowska, Julia ^a,f  

^a INSTITUTE OF GENERAL PATHOLOGY AND PATHOPHYSIOLOGY   (Russian Federation)

^b Institute for Atherosclerosis Research   (Russian Federation)

^c INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^d OHIO STATE UNIVERSITY   (United States)

^e UNIVERSITY OF HEIDELBERG   (Germany)

^f TOMSK STATE UNIVERSITY   (Russian Federation)

Author keywords

Activation; Atherosclerosis; Chemokine; Cytokine; Diagnostics; Immunopathology; Macrophage; Therapy

Indexed keywords

IMMUNOLOGIC AGENT; BETA CHEMOKINE; BIOLOGICAL MARKER; CCL18 PROTEIN, HUMAN; CHOLESTEROL; PLANT EXTRACT; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; ATHEROSCLEROSIS; CELL ACTIVATION; CELL POLARITY; CHRONIC INFLAMMATION; DISEASE ASSOCIATION; EX VIVO STUDY; HUMAN; IMMUNE SYSTEM; IMMUNOPATHOLOGY; INNATE IMMUNITY; MACROPHAGE; MACROPHAGE ACTIVATION; MONOCYTE; PRIMARY CULTURE; PRIORITY JOURNAL; BLOOD; DRUG DEVELOPMENT; DRUG EFFECTS; METABOLISM; MIDDLE AGED; PRIMARY CELL CULTURE; PROCEDURES;

ATHEROSCLEROSIS; BIOMARKERS; CHEMOKINES, CC; CHOLESTEROL; DRUG DISCOVERY; HUMANS; MACROPHAGES; MIDDLE AGED; MONOCYTES; PLANT EXTRACTS; PRIMARY CELL CULTURE; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84925876893     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612820666141013120459     Document Type: Article

References (57)

1. Darveau R. Infection, inflammation, and cancer. Nat Biotechnol 1999; 1: 19.
2. Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet 2001; 357: 539-45.
3. Balkwill FR. Re: Possible role of ovarian epithelial inflammation in ovarian cancer. J Natl Cancer Inst 2000; 92: 162-3.
4. Fries JF. Strategies for reduction of morbidity. Am J Clin Nutr 1992; 55: 1257S-62.
5. Beaglehole R., Bonita R. Global public health: a scorecard. Lancet 2008; 372: 1988-96.
6. Gratchev A, Sobenin I, Orekhov A, Kzhyshkowska J. Monocytes as a diagnostic marker of cardiovascular diseases. Immunobiol 2012; 217: 476-2.
7. Hurst NP, Nuki G. Evidence for defect of complement-mediated phagocytosis by monocytes from patients with rheumatoid arthritis and cutaneous vasculitis. BMJ 1981; 282: 2081-3.
8. Meuret G, Hoffmann G. Monocyte kinetic studies in normal and disease states. Br J Haematol 1973; 24: 275-85.
9. Meuret G, Bammert J, Hoffmann G. Kinetics of human monocytopoiesis. Blood 1974; 44-46: 801-16.
10. Averill LE, Meagher RC, Gerrity RG. Enhanced monocyte progenitor cell proliferation in bone marrow of hyperlipemic swine. Am J Pathol 1989; 135: 369-77.
11. Burke B, Lewis CE. The Macrophage. 3rd ed. Oxford: Oxford University Press 2008.
12. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-64.
13. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32: 593-604.
14. Gratchev A, Schledzewski K, Guillot P, Goerdt S. Alternatively activated antigen-presenting cells: molecular repertoire, immune regulation, and healing. Skin Pharmacol Appl Skin Physiol 2001; 14: 272-9.
15. Gordon S. The macrophage. Bioessays 1995; 17: 977-86.
16. Gratchev A, Kzhyshkowska J, Duperrier K, Utikal J, Velten FW, Goerdt S. The receptor for interleukin-17E is induced by Th2 cytokines in antigen-presenting cells. Scand J Immunol 2004; 60: 233-7.
17. Gratchev A, Kzhyshkowska J, Utikal J, Goerdt S. Interleukin-4 and dexamethasone counterregulate extracellular matrix remodelling and phagocytosis in type-2 macrophages. Scand J Immunol 2005; 61: 10-17.
18. Kodelja V, Muller C, Politz O, Hakij N, Orfanos CE, Goerdt S. Alternative macrophage activation-associated CC-chemokine-1, a novel structural homologue of macrophage inflammatory protein-1 alpha with a Th2-associated expression pattern. J Immunol 1998; 160: 1411-8.
19. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002; 10: 417-26.
20. Moore KJ, Tabas I. Macrophages in the pathogenesis of atherosclerosis. Cell 2011; 145: 341-55.
21. Gavrilin MA, Mitra S, Seshadri S, et al. Pyrin critical to macrophage IL-1beta response to Francisella challenge. J Immunol 2009; 182: 7982-9.
22. Sarkar A, Mitra S, Mehta S, Raices R, Wewers MD. Monocyte derived microvesicles deliver a cell death message via encapsulated caspase-1. PLoS One 2009; 4: e7140.
23. Gavrilin MA, Abdelaziz DH, Mostafa M, et al. Activation of the pyrin inflammasome by intracellular Burkholderia cenocepacia. J Immunol 2012; 188: 3469-77.
24. Snalhoub J, Falck-Hansen MA, Davies AH. Innate immunity and monocyte-acrophages activation in atherosclerosis. J Inflamm 2011; 8: 9.
25. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009; 27: 229-65.
26. Janeway CA, Jr, Medzhitov R. Innate immune recognition. Annu Rev Immunol 2002; 20: 197-216.
27. Valtonen VV. Infection as a risk factor for infarction and atherosclerosis. Annals of Medicine 1991; 23: 539-43.
28. Luque A, Turu MM, Rovira N, Juan-Babot JO, Slevin M, Krupinski J. Early atherosclerotic plaques show evidence of infection by Chlamydia pneumoniae. Front Biosci (Elite Ed) 2012; 4: 2423-32.
29. Charakida M, Tousoulis D. Infections and atheromatous plaque: current therapeutic implications. Curr Pharm Des 2013; 19: 1638-50.
30. Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010; 464: 1357-61.
31. Rajamäki K, Lappalainen J, Oörni K, et al. Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation. PLoS One 2010; 5: e11765.
32. Krishnan E. Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. Rheumatol 2010; 49: 1229-38.
33. Razani B, Feng C, Coleman T, et al. Autophagy links inflammasomes to atherosclerotic progression. Cell Metab 2012; 15: 534-44.
34. Strasser EF, Eckstein R. Optimization of leukocyte collection and monocyte isolation for dendritic cell culture. Transfus Med Rev 2010; 24: 130-9.
35. Clarkson SB, Ory PA. Developmentally regulated IgG Fc receptors on cultured human monocytes. J Exp Med 1988; 167: 408-20.
36. Baumgartner I, Scheiner O, Holzinger C, et al. Expression of the VEP13 antigen (CD16) on native human alveolar macrophages and cultured blood monocytes. Immunobiol 1988; 177: 317-26.
37. Krause S, Pohl A, Pohl C, et al. Ex vivo investigation of blood monocyte and platelet behaviour in pigs maintained on an atherogenic diet. Exp Pathol 1992; 44: 144-6.
38. Mosig S, Rennert K, Krause S, et al. Different functions of monocyte subsets in familial hypercholesterolemia: potential function of CD14+ CD16+ monocytes in detoxification of oxidized LDL. FASEB J 2009; 23: 866-74.
39. Bell FP, Gerrity RG. Evidence for an altered lipid metabolic state in circulating blood monocytes under conditions of hyperlipemia in swine and its implications in arterial lipid metabolism. Arterioscler Thromb 1992; 12: 155-62.
40. Gratchev A, Guillot P, Hakiy N, et al. Alternatively activated macrophages differentially express fibronectin and its splice variants and the extracellular matrix protein betaIG-H3. Scand J Immunol 2001; 53: 386-92.
41. Stein M, Keshav S, Harris N, Gordon S. Interleukin 4 potently enhances murine macrophage mannose receptor activity: a marker of alternative immunologic macrophage activation. J Exp Med 1992; 176: 287-92.
42. Politz O, Gratchev A, McCourt PA, et al. Stabilin-1 and-2 constitute a novel family of fasciclin-like hyaluronan receptor homologues. Biochem J 2002; 362: 155-64.
43. Schaer DJ, Boretti FS, Hongegger A, et al. Molecular cloning and characterization of the mouse CD163 homologue, a highly glucocorticoid-inducible member of the scavenger receptor cysteine-rich family. Immunogenetics 2001; 53: 170-7.
44. Gratchev A, Kzhyshkowska J, Köthe K, et al. Mphi1 and Mphi2 can be re-polarized by Th2 or Th1 cytokines, respectively, and respond to exogenous danger signals. Immunobiol 2006; 211: 473-86.
45. Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol 2008; 8: 958-69.
46. Pyonteck SM, Akkari L, Schuhmacher AJ, et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat Med 2013; 19: 1264-72.
47. Andreeva ER, Pugach IM, Orekhov AN. Subendothelial smooth muscle cells of human aorta express macrophage antigen in situ and in vitro. Atherosclerosis 1997; 135: 19-27.
48. Andreeva ER, Pugach IM, Orekhov AN.Collagen-synthesizing cells in initial and advanced atherosclerotic lesions of human aorta. Atherosclerosis 1997; 130: 133-42.
49. Tertov VV, Orekhov AN. Metabolism of native and naturally occurring multiple modified low density lipoprotein in smooth muscle cells of human aortic intima. Exp Mol Pathol 1997; 64: 127-45.
50. Tertov VV, Bittolo-Bon G, Sobenin IA, Cazzolato G, Orekhov AN, Avogaro P. Naturally occurring modified low density lipoproteins are similar if not identical: more electronegative and desialylated lipoprotein subfractions. Exp Mol Pathol 1995; 62: 166-72.
51. Jaakkola O, Solakivi T, Tertov VV, Orekhov AN, Miettinen TA, Nikkari T. Characteristics of low-density lipoprotein subfractions from patients with coronary artery disease. Coron Artery Dis 1993; 4: 379-85.
52. Tertov VV, Kaplun VV, Sobenin IA, Boytsova EY, Bovin NV, Orekhov AN. Human plasma trans-sialidase causes atherogenic modification of low density lipoprotein. Atherosclerosis 2001; 159: 103-15.
53. Kacharava AG, Tertov VV, Orekhov AN. Autoantibodies against low-density lipoprotein and atherogenic potential of blood. Ann Med 1993; 25: 551-5.
54. Orekhov AN, Tertov VV, Khashimov KHA, Kudryashov SA, Smirnov VN. Evidence of anti-atherosclerotic action of verapamil from direct effects on arterial cells. Am J Cardiol 1987; 59: 495-6.
55. Akopov SE, Orekhov AN, Tertov VV, Khashimov KA, Gabrielyan ES, Smirnov VN. Stable analogues of prostacyclin and thromboxane A2 display contradictory influences on atherosclerotic properties of cells cultured from human aorta. The effect of calcium antagonists. Atherosclerosis 1988; 72: 245-8.
56. Orekhov AN, Tertov VV, Khashimov KHA, Kudryashov SA, Smirnov VN. Antiatherosclerotic effects of verapamil in primary culture of human aortic intimal cells. J Hypertens 1986; 4: S153-5.
57. Chazov EI, Tertov VV, Orekhov AN, et al. Atherogenicity of blood serum from patients with coronary heart disease. Lancet 1986; 2: 595-8.